{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:00:26Z","timestamp":1793152826534,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113388","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:33:04Z","timestamp":1728909184000},"page":"113388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"P1","title":["Current therapeutic overview and future perspectives regarding the treatment of psoriasis"],"prefix":"10.1016","volume":"143","author":[{"given":"Francesco","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Verduci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Laconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mangione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Carlevatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Capuozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Langella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.intimp.2024.113388_b0005","doi-asserted-by":"crossref","first-page":"8575","DOI":"10.3390\/ijms23158575","article-title":"Vitamin D signaling in psoriasis: pathogenesis and therapy","volume":"23","author":"Bro\u017cyna","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8 Suppl","key":"10.1016\/j.intimp.2024.113388_b0010","first-page":"s238","article-title":"Managed care aspects of psoriasis and psoriatic arthritis","volume":"22","author":"Evans","year":"2016","journal-title":"Am. J. Manag. Care"},{"issue":"369","key":"10.1016\/j.intimp.2024.113388_b0015","article-title":"Global psoriasis atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"28","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.intimp.2024.113388_b0020","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"16","author":"Damiani","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"issue":"8","key":"10.1016\/j.intimp.2024.113388_b0025","doi-asserted-by":"crossref","first-page":"103359","DOI":"10.1016\/j.autrev.2023.103359","article-title":"Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.reuma.2017.07.004","article-title":"Severity indices in rheumatoid arthritis: a systematic review","volume":"15","author":"Toledano","year":"2019","journal-title":"Reumatol. Clin. (Engl. Ed.)"},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0035","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.3390\/ijms23052859","article-title":"Leptin in osteoarthritis and rheumatoid arthritis: player or bystander?","volume":"23","author":"Ait Eldjoudi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.intimp.2024.113388_b0040","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.intimp.2024.113388_b0045","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.23513","article-title":"Comparison of perceptions of skin condition, product use and allergen reactivity between people with psoriasis and controls in the European dermato-epidemiology network (EDEN) fragrance study","volume":"104","author":"Cassalia","year":"2024","journal-title":"Acta Derm. Venereol."},{"issue":"10275","key":"10.1016\/j.intimp.2024.113388_b0050","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0055","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0060","first-page":"122","article-title":"Etanercept induces remission of polyarteritis nodosa: a case report","volume":"3","author":"Capuozzo","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"115779","key":"10.1016\/j.intimp.2024.113388_b0065","article-title":"Decoding clinical and molecular pathways of liver dysfunction in Psoriatic Arthritis: impact of cumulative methotrexate doses","volume":"168","author":"Ruiz-Ponce","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.intimp.2024.113388_b0070","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2024.113388_b0075","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1093\/rheumatology\/keab834","article-title":"mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors","volume":"61","author":"Zhang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.intimp.2024.113388_b0080","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/sj.jid.5701255","article-title":"Polymorphisms of the IL12B and IL23R genes are associated with psoriasis","volume":"128","author":"Nair","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"10370","key":"10.1016\/j.intimp.2024.113388_b0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.intimp.2024.113388_b0090","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/03007995.2023.2228613","article-title":"Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients","volume":"39","author":"Mahmoud","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0095","doi-asserted-by":"crossref","first-page":"e003855","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40259-020-00416-z","article-title":"Certolizumab pegol: a review in moderate to severe plaque psoriasis","volume":"34","author":"Lee","year":"2020","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0105","first-page":"146","article-title":"Functional study of TNF-\u03b1 as a promoter of polymorphisms in psoriasis","volume":"157","author":"Dapr\u00e0","year":"2022","journal-title":"Ital. J. Dermatol. Venerol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0110","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0115","article-title":"The role of helper T cells in psoriasis","volume":"15","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0120","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1038\/s41598-019-43899-9","article-title":"Th1, Th17, and treg responses are differently modulated by TNF-\u03b1 inhibitors and methotrexate in psoriasis patients","volume":"9","author":"Furiati","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2024.113388_b0125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.1901358","article-title":"TNF-\u03b1 regulates human plasmacytoid dendritic cells by suppressing IFN-\u03b1 production and enhancing T cell activation","volume":"206","author":"Psarras","year":"2021","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00296-016-3436-0","article-title":"Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies","volume":"36","author":"Elyoussfi","year":"2016","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2024.113388_b0135","article-title":"Mast cells express IL17A, IL17F and RORC, are activated and persist with IL-17 production in resolved skin of patients with chronic plaque-type psoriasis","author":"Benezeder","year":"2024","journal-title":"Res. Sq. [Preprint]"},{"key":"10.1016\/j.intimp.2024.113388_b0140","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-024-01112-4","article-title":"Regulation of the immune cell repertoire in psoriasis patients upon blockade of IL-17A or TNF\u03b1","author":"Tittes","year":"2024","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"14","key":"10.1016\/j.intimp.2024.113388_b0145","doi-asserted-by":"crossref","first-page":"1286344","DOI":"10.3389\/fimmu.2023.1286344","article-title":"Crosstalk: keratinocytes and immune cells in psoriasis","volume":"9","author":"Kamata","year":"2023","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.intimp.2024.113388_b0150","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150223","article-title":"Abnormal lipid metabolism in epidermal Langerhans cells mediates psoriasis-like dermatitis","volume":"7","author":"Zhang","year":"2022","journal-title":"JCI Insight."},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0155","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12026-022-09356-y","article-title":"Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data","volume":"71","author":"Ruggiero","year":"2023","journal-title":"Immunol. Res."},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0160","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/ph15121544","article-title":"Progranulin in musculoskeletal inflammatory and degenerative disorders, focus on rheumatoid arthritis, lupus and intervertebral disc disease: a systematic review","volume":"15","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.intimp.2024.113388_b0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cyto.2019.02.018","article-title":"IL-23 and dendritic cells: what are the roles of their mutual attachment in immune response and immunotherapy?","volume":"120","author":"Li","year":"2019","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.intimp.2024.113388_b0170","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside","volume":"17","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0175","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.17219\/acem\/112604","article-title":"Serum concentration of osteopontin and interleukin 17 in psoriatic patients","volume":"29","author":"Przepi\u00f3rka-Kosi\u0144ska","year":"2020","journal-title":"Adv. Clin. Exp. Med."},{"issue":"2020","key":"10.1016\/j.intimp.2024.113388_b0185","article-title":"IL-17A in the psoriatic patients' serum and plaque scales as potential marker of the diseases severity and obesity","volume":"5","author":"Michalak-Stoma","year":"2020","journal-title":"Mediators Inflamm."},{"issue":"13","key":"10.1016\/j.intimp.2024.113388_b0190","article-title":"Interleukin-17 as a potential therapeutic target for chronic pain","volume":"29","author":"Jiang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113388_b0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00712.x","article-title":"Th17 cytokines and their emerging roles in inflammation and autoimmunity","volume":"226","author":"Fouser","year":"2008","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2024.113388_b0200","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.113388_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222969","article-title":"Interleukin (IL)-17\/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses","volume":"15","author":"Mercurio","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11926-019-0866-1","article-title":"Psoriatic arthritis: newer and older therapies","volume":"21","author":"Chao","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0215","article-title":"Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis","volume":"6","author":"Lu","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0220","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jdv.15258","article-title":"Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0225","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2019.1566456","article-title":"Etanercept biosimilar SB-4","volume":"19","author":"Pelechas","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"issue":"15","key":"10.1016\/j.intimp.2024.113388_b0230","first-page":"375","article-title":"Adalimumab therapy in a patient with psoriasis, down syndrome, and concomitant hepatitis B virus infection","volume":"1","author":"Madani","year":"2021","journal-title":"Biologics."},{"issue":"7","key":"10.1016\/j.intimp.2024.113388_b0235","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/09546634.2019.1605143","article-title":"Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis","volume":"31","author":"Carubbi","year":"2020","journal-title":"J. Dermatolog. Treat."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0240","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00063030-200923020-00005","article-title":"Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"23","author":"Oldfield","year":"2009","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0245","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.4110\/in.2024.24.e4","article-title":"TNF in human tuberculosis: a double-edged sword","volume":"24","author":"Yuk","year":"2024","journal-title":"Immune Netw."},{"issue":"13","key":"10.1016\/j.intimp.2024.113388_b0250","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-017-0800-7","article-title":"Guselkumab: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0255","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001457","article-title":"Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced","volume":"7","author":"Ritchlin","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.intimp.2024.113388_b0260","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.18672","article-title":"Guselkumab in patients with scalp psoriasis: a post hoc analysis of the VOYAGE 2 phase III randomized clinical trial","volume":"104","author":"Sonkoly","year":"2024","journal-title":"Acta Derm. Venereol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0265","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaad.2020.09.047","article-title":"Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"84","author":"Lebwohl","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0270","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/09546634.2020.1773382","article-title":"Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States","volume":"33","author":"Jia","year":"2022","journal-title":"J. Dermatolog. Treat."},{"issue":"10198","key":"10.1016\/j.intimp.2024.113388_b0275","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.intimp.2024.113388_b0280","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0285","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjd\/ljac040","article-title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials","volume":"188","author":"Langley","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0295","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40257-016-0246-9","article-title":"Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3)","volume":"18","author":"Blauvelt","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113388_b0300","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.14237","article-title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)","volume":"31","author":"Menter","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0305","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40257-018-0408-z","article-title":"Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: results from the pooled AMAGINE-2\/-3 randomized trials","volume":"20","author":"McMichael","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"issue":"10273","key":"10.1016\/j.intimp.2024.113388_b0310","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0315","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0320","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 6","key":"10.1016\/j.intimp.2024.113388_b0325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-3083.2010.03830.x","article-title":"Novel biologic therapies in development targeting IL-12\/IL-23","volume":"24","author":"van de Kerkhof","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"9625","key":"10.1016\/j.intimp.2024.113388_b0330","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.intimp.2024.113388_b0335","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0340","article-title":"A systematic review evaluating the effectiveness of several biological therapies for the treatment of skin psoriasis","volume":"15","author":"Alzahrani","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0345","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/1744666X.2021.1886081","article-title":"The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives","volume":"17","author":"Iznardo","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0350","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/1744666X.2023.2195165","article-title":"Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis","volume":"19","author":"Burden","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0355","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s13555-023-01037-4","article-title":"Efficacy and safety of spesolimab in patients with generalized pustular psoriasis: a subgroup analysis of Chinese patients in the effisayil 1 trial","volume":"13","author":"Tsai","year":"2023","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0360","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40259-023-00587-5","article-title":"Targeting IL-36 in inflammatory skin diseases","volume":"37","author":"Fukaura","year":"2023","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0365","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.jaad.2022.10.058","article-title":"Response to the article by Naik et al entitled \u201canakinra for refractory pustular psoriasis: a phase II, open label, dose-escalation trial\u201d","volume":"88","author":"Yatsuzuka","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0370","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40257-022-00698-9","article-title":"Generalized pustular psoriasis in pregnancy: current and future treatments","volume":"23","author":"Seishima","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0375","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/ced.12759","article-title":"Palmoplantar pustular psoriasis unresponsive to the interleukin-1\u03b2 antagonist canakinumab","volume":"41","author":"Mansouri","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"issue":"6 Suppl 1","key":"10.1016\/j.intimp.2024.113388_b0380","first-page":"44","article-title":"Janus kinase inhibitors: safety in patients with psoriatic arthritis","volume":"49","author":"Nash","year":"2022","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113388_b0385","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s10067-023-06529-4","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"42","author":"Yang","year":"2023","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/1756-185X.14447","article-title":"Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis","volume":"26","author":"Harkins","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0395","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00393-021-01119-8","article-title":"Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis","volume":"82","author":"Lee","year":"2023","journal-title":"Z Rheumatol."},{"key":"10.1016\/j.intimp.2024.113388_b0400","doi-asserted-by":"crossref","DOI":"10.1007\/s10787-024-01453-8","article-title":"Atopic dermatitis: treatment and innovations in immunotherapy","author":"Ferrara","year":"2024","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2024.113388_b0405","doi-asserted-by":"crossref","DOI":"10.1007\/s13671-024-00423-1","article-title":"Innovative immunotherapy for the treatment of atopic dermatitis: focus on the European and Latin American regulatory frameworks","author":"Ferrara","year":"2024","journal-title":"Curr. Derm. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0410","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s10067-024-06940-5","article-title":"Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Dai","year":"2024","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0415","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10067-021-05894-2","article-title":"Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials","volume":"41","author":"Kivitz","year":"2022","journal-title":"Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113388_b0420","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0425","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","article-title":"Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program","volume":"44","author":"Conaghan","year":"2021","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0430","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0435","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0440","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1_suppl","key":"10.1016\/j.intimp.2024.113388_b0445","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/12034754221141680","article-title":"Clinical implications of targeting the JAK-STAT pathway in psoriatic disease: emphasis on the TYK2 pathway","volume":"27","author":"Loo","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0450","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0455","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0460","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/cts.12929","article-title":"Safety and pharmacokinetics of the oral TYK2 inhibitor PF-06826647: a phase I, randomized, double-blind, placebo-controlled, dose-escalation study","volume":"14","author":"Singh","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.113388_b0465","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2665-9913(20)30397-0","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study","volume":"3","author":"Tehlirian","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0470","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase iia, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2024.113388_b0475","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.19811","article-title":"COMFORT-1 Study Investigators. Efficacy and safety of piclidenoson in plaque psoriasis: results from a randomized phase 3 clinical trial (COMFORT-1)","author":"Papp","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113388_b0480","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.4049\/jimmunol.1602142","article-title":"Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10","volume":"198","author":"Zanin-Zhorov","year":"2017","journal-title":"J. Immunol."},{"issue":"24","key":"10.1016\/j.intimp.2024.113388_b0485","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc) inhibitors: hits and misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2024.113388_b0490","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/17460441.2021.1948833","article-title":"Retinoic acid-related orphan receptor gamma t (ROR\u03b3t) inverse agonists\/antagonists for the treatment of inflammatory diseases - where are we presently?","volume":"16","author":"Gege","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"issue":"250","key":"10.1016\/j.intimp.2024.113388_b0495","article-title":"Advances in the development of phosphodiesterase-4 inhibitors","volume":"15","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-014-0005-4","article-title":"Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis","volume":"1","author":"Mease","year":"2014","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113388_b0510","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10066","key":"10.1016\/j.intimp.2024.113388_b0515","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Efficacy and safety of guselkumab, an anti\u2013interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of moderate to severe psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial (VOYAGE 1)","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"9997","key":"10.1016\/j.intimp.2024.113388_b0520","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.113388_b0525","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/pharmaceutics16010111","article-title":"Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents","volume":"16","author":"Drakos","year":"2024","journal-title":"Pharmaceutics."},{"issue":"13","key":"10.1016\/j.intimp.2024.113388_b0530","article-title":"New and emerging oral therapies for psoriasis","volume":"1","author":"Yilmaz","year":"2024","journal-title":"Drugs Context"},{"key":"10.1016\/j.intimp.2024.113388_b0535","unstructured":"Clinical Trials, 2024, https:\/\/clinicaltrials.gov\/ (accessed September 2024)."},{"issue":"2","key":"10.1016\/j.intimp.2024.113388_b0540","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10557-021-07251-6","article-title":"Low molecular weight heparin, anti-inflammatory\/immunoregulatory and antiviral effects, a short update","volume":"37","author":"Vitiello","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"5","key":"10.1016\/j.intimp.2024.113388_b0545","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/ijp.IJP_417_20","article-title":"Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?","volume":"52","author":"Ferrara","year":"2020","journal-title":"Indian J. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T03:53:45Z","timestamp":1729655625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924019106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":109,"alternative-id":["S1567576924019106"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113388","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current therapeutic overview and future perspectives regarding the treatment of psoriasis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113388"}}